The Convergence of Medical Devices & Drugs: Advances in Drug Delivery May 3, 2018 12:00 PM – 5:00 PM, Westin Hotel, Waltham, MA
Westin Waltham Boston 70 3rd Avenue Waltham MA US 02451LPBI Group will cover the event in Real Time
Aviva Lev-Ari, PhD, RN will be in attendance
- e-Scientific Publishing: The Competitive Advantage of a Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing – LPBI Group, A Case in Point – Updated on 4/2/2018
- Recollections: My days at Berkeley, 9/1978 – 12/1983 – About my doctoral advisor, Allan Pred, other Professors and other Peers
- Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018
MassBio’s second annual Medical Device Event will focus on opportunities and advances in drug delivery, including the unique developmental and regulatory challenges these products face, the many scientific advances in the space and new opportunities for funding. Panelists will discuss innovation and commercialization strategies.
Advances in drug delivery technologies are improving the safety and efficacy of new and existing therapies. The success of many new therapies in development is contingent on the development of effective delivery systems. Traditional drug delivery methods won’t work for some compounds and biologics. Stability issues create challenges for storage and transport. There are opportunities for combination drug delivery products to extend the patent life of drugs on the market. From diffusion based polymer systems to complex delivery devices utilizing diagnostic sensors and sophisticated control systems for precise and timely delivery of life-saving agents, a diverse set of scientific and engineering disciplines are being brought to bear within this space. However, combination products involve components that would normally be developed under different types of regulations, design criteria, and controls. This symposium will explore many of the diverse aspects impacting drug delivery products.
This event will feature an active exhibit hall, panel discussions, a keynote speaker and networking sessions. This is an excellent opportunity for companies to reach a diverse audience that represents nearly every aspect of the life sciences industry, including academic researchers, entrepreneurs, device engineers and biopharma executives.
Clinicians will discuss the medical challenges for which drug delivery innovations have provided a unique solution. Academic researchers will discuss scientific advances which may lead to breakthrough products. Entrepreneurs will discuss strategies for funding new product ventures, and development issues specific to drug delivery products. Corporate speakers will discuss the challenges across the value chain of manufacturing and selling combination products globally. Regulatory speakers will address current thinking and approaches to drug delivery products within government agencies, both US and internationally.
SOURCE
Registration
12:00 pm – 12:30 pm
Opening Remarks
Keynote Presentation
Innovation & Development Panel
Networking Break
Commercialization Pathways Panel
Networking Reception
4:30 pm – 5:30 pm
Speakers
- Jessica Ballinger, Chief Operating Officer, Lyndra
- Maria Berkman, MD, MBA, Director and Head of MedTech practice, Broadview Ventures
- Kristina Bieker-Brady, Ph.D., Partner, McDermott Will & Emery LLP
- Benjamin S. Bleier, MD, FACS, FARS, Associate Professor, Director of Endoscopic Skull Base Surgery, Co-Director Center for Thyroid Eye Disease and Orbital Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School
- Brent Buchine, Ph.D., Co-Founder and CTO, Windgap Medical, Inc.
- Michael J. Cima, Ph.D., Associate Dean of Innovation, MIT
- Bob Coughlin, President & CEO, MassBio
- Harry Glorikian, General Partner, New Ventures Funds
- Paul Just, PharmD, Senior Principal, Medical Device Health Economics, ICON plc
- Maria Palasis, President and CEO, 480 Biomedical, Inc.
- Pamela J. Weagraff, Director, MedTech Regulatory, IQVIA
- Andrew Wright, Vice President, Digital Medicine & Medical Device Division, Otsuka Pharmaceutical Companies
Leave a Reply